
Ahsan M. Arozullah MD MPH
Hospital Medicine/Hospitalist
Senior Medical Director, Global Medical Safety Oncology Therapeutic Area Group Lead
Join to View Full Profile
1740 W Taylor StChicago, IL 60612
Phone+1 866-600-2273
Fax+1 312-413-8950
Dr. Arozullah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1992 - 1995
- Northwestern University The Feinberg School of MedicineClass of 1992
Certifications & Licensure
- IL State Medical License 1995 - 2026
Publications & Presentations
PubMed
- 20 citationsILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.Samuel J Klempner, Keun-Wook Lee, Kohei Shitara, Jean-Phillippe Metges, Sara Lonardi
Clinical Cancer Research. 2023-10-02 - 179 citationsZolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger
Nature Medicine. 2023-08-01 - 181 citationsZolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junc...Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson
Lancet. 2023-05-20
Press Mentions
- Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment SettingApril 23rd, 2024
- First ADC/Immuno-Oncology Combination Approved for Urothelial CancerApril 4th, 2023
- After Rumored Merger Fell Through, Merck and Seagen's Padcev-Keytruda Combo Wins Bladder Cancer NodApril 3rd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: